261 related articles for article (PubMed ID: 7850598)
1. First-trimester Down's syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling.
Brambati B; Cislaghi C; Tului L; Alberti E; Amidani M; Colombo U; Zuliani G
Ultrasound Obstet Gynecol; 1995 Jan; 5(1):9-14. PubMed ID: 7850598
[TBL] [Abstract][Full Text] [Related]
2. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency.
Pandya PP; Kondylios A; Hilbert L; Snijders RJ; Nicolaides KH
Ultrasound Obstet Gynecol; 1995 Jan; 5(1):15-9. PubMed ID: 7850583
[TBL] [Abstract][Full Text] [Related]
4. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age.
Szabó J; Gellén J; Szemere G
Ultrasound Obstet Gynecol; 1995 Mar; 5(3):161-3. PubMed ID: 7788489
[TBL] [Abstract][Full Text] [Related]
5. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency.
Hafner E; Schuchter K; Philipp K
Ultrasound Obstet Gynecol; 1995 Nov; 6(5):330-3. PubMed ID: 8590203
[TBL] [Abstract][Full Text] [Related]
6. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
[TBL] [Abstract][Full Text] [Related]
7. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
8. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units.
Pandya PP; Goldberg H; Walton B; Riddle A; Shelley S; Snijders RJ; Nicolaides KH
Ultrasound Obstet Gynecol; 1995 Jan; 5(1):20-5. PubMed ID: 7850584
[TBL] [Abstract][Full Text] [Related]
9. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
Thilaganathan B; Slack A; Wathen NC
Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
[TBL] [Abstract][Full Text] [Related]
10. First trimester nuchal translucency: effective routine screening for Down's syndrome.
Thilaganathan B; Sairam S; Michailidis G; Wathen NC
Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
[TBL] [Abstract][Full Text] [Related]
11. Increased nuchal translucency as a marker for fetal chromosomal defects.
Taipale P; Hiilesmaa V; Salonen R; Ylöstalo P
N Engl J Med; 1997 Dec; 337(23):1654-8. PubMed ID: 9385124
[TBL] [Abstract][Full Text] [Related]
12. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
Noble PL; Abraha HD; Snijders RJ; Sherwood R; Nicolaides KH
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):390-5. PubMed ID: 8903913
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of fetal nuchal translucency.
Jackson M; Rose NC
Semin Roentgenol; 1998 Oct; 33(4):333-8. PubMed ID: 9800243
[TBL] [Abstract][Full Text] [Related]
14. [Molecular biology usefulness for rapid diagnosis of Down's syndrome and common aneuploidies].
Fauret AL; Bilan F; Patri S; Couet D; Marechaud M; Pierre F; Gilbert-Dussardier B; Kitzis A
Gynecol Obstet Fertil; 2009; 37(7-8):611-9. PubMed ID: 19574080
[TBL] [Abstract][Full Text] [Related]
15. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
[TBL] [Abstract][Full Text] [Related]
16. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
[TBL] [Abstract][Full Text] [Related]
17. [Screening for aneuploidy by first trimester nuchal translucency measurement: results from a prospective trial including 1980 cases in a single center in Switzerland].
Tercanli S; Holzgreve W; Batukan C; Gerber A; Ermis H; Miny P
Ultraschall Med; 2002 Feb; 23(1):22-6. PubMed ID: 11842368
[TBL] [Abstract][Full Text] [Related]
18. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
19. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.
Nicolaides KH; Azar G; Byrne D; Mansur C; Marks K
BMJ; 1992 Apr; 304(6831):867-9. PubMed ID: 1392745
[TBL] [Abstract][Full Text] [Related]
20. Trisomy 18: first-trimester nuchal translucency with pathological correlation.
Jackson S; Porter H; Vyas S
Ultrasound Obstet Gynecol; 1995 Jan; 5(1):55-6. PubMed ID: 7850592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
